Zobrazeno 1 - 10
of 62
pro vyhledávání: '"Charles, Phelps"'
Autor:
Institute of Medicine, Board on Global Health, Board on Population Health and Public Health Practice, Committee on Identifying and Prioritizing New Preventive Vaccines for Development, Lonnie King, Rose Marie Martinez, Tracy Lieu, Dennis Fryback, Charles Phelps, Kinpritma Sangha, Guruprasad Madharan
As a number of diseases emerge or reemerge thus stimulating new vaccine development opportunities to help prevent those diseases, it can be especially difficult for decision makers to know where to invest their limited resources. Therefore, it is inc
Autor:
Charles Phelps, Guruprasad Madhavan
Publikováno v:
Cost Effectiveness and Resource Allocation, Vol 16, Iss S1, Pp 1-7 (2018)
Abstract Background Cost–benefit and cost-effectiveness analysis place limits on the dimensions of value that the models can incorporate. Cost–benefit analysis requires monetization of all measures of value (including life), a task sometimes deem
Externí odkaz:
https://doaj.org/article/2ec282aee3a04157bb97a6a21f3b5e2a
Autor:
Pier Luigi Zinzani, Muhit Özcan, Marcelo Capra, Armando Santoro, Panayiotis Panayiotidis, Krimo Bouabdallah, Wojciech Jurczak, Charles Phelps, Florian JR Hiemeyer, Lidia Mongay Soler, Jose Garcia-Vargas, Barrett H. Childs, Georg Lenz, Matthew J. Matasar, Martin Dreyling
Publikováno v:
Blood. 140:6470-6473
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::8381c7574c90effb8ae1911cddd54674
https://doi.org/10.1182/blood-2022-167368
https://doi.org/10.1182/blood-2022-167368
Autor:
Charles Phelps
Publikováno v:
Journal of Risk and Insurance. 90:213-241
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::2e1afdf2037764f8e5be119a33436c9b
https://doi.org/10.1111/jori.12377
https://doi.org/10.1111/jori.12377
Autor:
Udai Banerji, Johann S. de Bono, T.R. Jeffry Evans, John Camm, Charles Phelps, Ann Forslund, Johan W. Smit, Steve Mcclue, Yusri Elsayed, Peter Hellemans, Nele Fourneau, Adam Stewart, Richard Cowan, Ruth Plummer, Rebecca S. Kristeleit, Richard Baird, Balaji Venugopal
Supplementary Legend - PDF file 66K, Supplementary legend
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::93bd9512e90e8428b684e29321f17aee
https://doi.org/10.1158/1078-0432.22449674
https://doi.org/10.1158/1078-0432.22449674
Autor:
Udai Banerji, Johann S. de Bono, T.R. Jeffry Evans, John Camm, Charles Phelps, Ann Forslund, Johan W. Smit, Steve Mcclue, Yusri Elsayed, Peter Hellemans, Nele Fourneau, Adam Stewart, Richard Cowan, Ruth Plummer, Rebecca S. Kristeleit, Richard Baird, Balaji Venugopal
Purpose: To determine the maximum-tolerated dose (MTD), dose-limiting toxicities (DLT), and pharmacokinetic and pharmacodynamic profile of quisinostat, a novel hydroxamate, pan-histone deacetylase inhibitor (HDACi).Experimental Design: In this first-
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c32c02ec5d8571cf1af10f27c04572d3
https://doi.org/10.1158/1078-0432.c.6521723
https://doi.org/10.1158/1078-0432.c.6521723
Autor:
Udai Banerji, Johann S. de Bono, T.R. Jeffry Evans, John Camm, Charles Phelps, Ann Forslund, Johan W. Smit, Steve Mcclue, Yusri Elsayed, Peter Hellemans, Nele Fourneau, Adam Stewart, Richard Cowan, Ruth Plummer, Rebecca S. Kristeleit, Richard Baird, Balaji Venugopal
Supplementary Table 2 - PDF file 58K, A summary of PK parameters of quisinostat estimated on day 1
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5abd1da2e5d291dae19258963466470c
https://doi.org/10.1158/1078-0432.22449668.v1
https://doi.org/10.1158/1078-0432.22449668.v1
Autor:
Udai Banerji, Johann S. de Bono, T.R. Jeffry Evans, John Camm, Charles Phelps, Ann Forslund, Johan W. Smit, Steve Mcclue, Yusri Elsayed, Peter Hellemans, Nele Fourneau, Adam Stewart, Richard Cowan, Ruth Plummer, Rebecca S. Kristeleit, Richard Baird, Balaji Venugopal
Supplementary Figure 1a,b - PDF file 45K, Plasma concentration-time profile of 12 mg quisinostat on (a) day 1 and (b) at steady state for MWF treatment schedule
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4e0706cd6567a0bafdcd4d473361bc5f
https://doi.org/10.1158/1078-0432.22449677
https://doi.org/10.1158/1078-0432.22449677
Autor:
Udai Banerji, Johann S. de Bono, T.R. Jeffry Evans, John Camm, Charles Phelps, Ann Forslund, Johan W. Smit, Steve Mcclue, Yusri Elsayed, Peter Hellemans, Nele Fourneau, Adam Stewart, Richard Cowan, Ruth Plummer, Rebecca S. Kristeleit, Richard Baird, Balaji Venugopal
Supplementary Table 1 - PDF file 54K, Number (percentage) of patients exhibiting increased ventricular ectopic activity
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3bc3771585f876d8b010770be7fcfcb2
https://doi.org/10.1158/1078-0432.22449671
https://doi.org/10.1158/1078-0432.22449671
Autor:
Christopher Cinatl, William Ondo, Brian Koo, Karla Dzienkowski, Jeffrey Durmer, Charles Phelps, John Winkelman
Publikováno v:
Sleep. 45:A241-A241
Introduction RLS affects 5%-10% of European and North American adults, with 2%-3% experiencing moderate to severe symptoms. RLS patients, often undiagnosed or improperly treated, experience significant depression in addition to loss of sleep. Methods
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::a5e04249a3de4985520a2ef1d671c067
https://doi.org/10.1093/sleep/zsac079.544
https://doi.org/10.1093/sleep/zsac079.544